Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: This work aimed to study natural humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Methods: Chemiluminescent immunoassay (CLIA) was used to detect the neutralizing antibody (Nabs) and IgG.
Results: Nabs peaked on days 57-96 after symptom onset and remained detected on days 97-132. The Nabs in the 32 patients who were dynamically monitored showed four changing patterns. The titers of Nabs and IgG were correlated, and three modes of relationship were found between them.
Conclusions: Nabs showed a regular change in the course of coronavirus disease 2019 (COVID-19). The detection of Nabs is very important for monitoring the course of COVID-19 and predicting the strength of antibody protection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10734152 | PMC |
| http://dx.doi.org/10.1186/s12879-023-08465-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mutations in feline infectious peritonitis virus nonstructural protein 14/16 methyltransferase attenuate the pathogenicity of the virus in cats.
J Virol
September 2025
National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.
Feline infectious peritonitis virus (FIPV) can cause an immune-mediated disease that is fatal to felines, but there is a lack of clinically effective protection conferred by vaccines. The methyltransferase (MTase) activity of the coronavirus nonstructural proteins nsp14 and nsp16 affects virulence, but there are no studies on the effect of nsp14 and nsp16 mutations affecting enzyme activity on the virulence of FIPV. In this study, we successfully rescued two mutant strains based on the previous infectious clone QS-79, named FIPV QS-79 dnsp14 and dnsp16, by mutating the MTase active sites of nsp14 (N415) and nsp16 (D129).
View Article and Find Full Text PDFBayesian estimation of HIV acquisition dates for prevention trials.
mBio
September 2025
Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA.
Accurate timing estimates of when participants acquire HIV in HIV prevention trials are necessary for determining antibody levels at acquisition. The Antibody-Mediated Prevention (AMP) Studies showed that a passively administered broadly neutralizing antibody can prevent the acquisition of HIV from a neutralization-sensitive virus. We developed a pipeline for estimating the date of detectable HIV acquisition (DDA) in AMP Study participants using diagnostic and viral sequence data.
View Article and Find Full Text PDFLow Levels of Neutralizing Antibodies to Influenza A (H5N1) and D Viruses Among Cattle and Cattle Workers on US Farms, 2024-2025.
Influenza Other Respir Viruses
September 2025
Department of Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA.
Coxsackie B1 virus-like particle vaccine modified to exclude a highly conserved immunoreactive region from the capsid induces potent neutralizing antibodies and protects against infection in mice.
J Biomed Sci
September 2025
Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Background: Enteroviruses, including Coxsackie B (CVB) viruses, can cause severe diseases such as myocarditis, pancreatitis, and meningitis. Vaccines can prevent these complications, but conserved non-neutralizing epitopes in the viral capsid may limit their effectiveness. The immunodominant PALXAXETG motif, located in the VP1 N-terminus, is a highly conserved region in enteroviruses that elicits non-neutralizing antibody responses.
View Article and Find Full Text PDFAnti-M1R/B6R antibody characterization and bispecific design for enhanced orthopoxvirus protection.
EMBO Mol Med
September 2025
Institute of Physical Science and Information, Anhui University, 230039, Hefei, Anhui, China.
The global outbreak of the mpox in humans, caused by the mpox virus (MPXV), underscores the urgent need for safe and effective therapeutics. In this study, we characterized the dominant MPXV immunogens, M1R and B6R, by sequencing monoclonal antibodies (MAbs) from the immunized mice and analyzing their epitopes and functions through in vitro and in vivo assessments of binding and antiviral activities. Several broadly effective anti-M1R and anti-B6R neutralizing MAbs were identified and they exhibited enhanced antiviral effects against MPXV or vaccinia virus (VACV) when used in antibody cocktail and bispecific antibody designs.
View Article and Find Full Text PDF